Dr. Camidge Discusses Unmet Needs in ALK+ Lung Cancer

D. Ross Camidge, MD, PhD
Published: Wednesday, Nov 01, 2017



D. Ross Camidge, MD, PhD, a professor of medical oncology at the University of Colorado, discusses unmet needs for patients with ALK-positive lung cancer.

In a setting with a plethora of ALK inhibitors, the first task to identify other pathways of resistance, and then develop rational combinations to target them.

Though many patients do well with ALK inhibitors, some do not, and the only options for them are either creative use of radiotherapy or platinum pemetrexed-based chemotherapy, Camidge says.
 


D. Ross Camidge, MD, PhD, a professor of medical oncology at the University of Colorado, discusses unmet needs for patients with ALK-positive lung cancer.

In a setting with a plethora of ALK inhibitors, the first task to identify other pathways of resistance, and then develop rational combinations to target them.

Though many patients do well with ALK inhibitors, some do not, and the only options for them are either creative use of radiotherapy or platinum pemetrexed-based chemotherapy, Camidge says.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™: Choosing Therapies for Patients with EGFR-mutant Lung Cancers: More Options... More Decisions... Better OutcomesApr 27, 20182.0
Community Practice Connections™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations Across Lung, Head and Neck, and Bladder CancersApr 28, 20182.0
Publication Bottom Border
Border Publication
x